The chemiluminescence-based immunoassay is used for the direct quantitative measurement of free testosterone in serum or plasma, with results in 48 minutes.
The NCI-led Vanguard study has selected tests from Guardant Health and ClearNote Health to move forward after a vigorous technology assessment. The company recently published data demonstrating its ...
Innovaccer on Thursday announced separately that it has closed a $275 million Series F funding round that includes participation from Danaher Ventures and others.